Extracts from the fungus Guignardia sp., their uses in pharmaceutical compositions, new isolate compound from the extract of the fungus Gignardia sp. and its use in pharmaceutical compositions

Abstract

The present invention refers to extracts from the fungus Guignardia sp., and also a new isolate compound from the aforementioned extract, both having antimicrobial activities, particularly antibacterial and antifungal activities, and their use in pharmaceutical compositions. The new compound, isolated from the extract of the fungus Guignardia sp., presents a dioxolanone ring, having the following formula:

1 . Aqueous raw extract or organic raw extract with pharmacological activity characterised by the fact of being obtained from an aqueous or organic solvent extraction of the filtrate, which is removed from the fermentation of the fungus Guignardia.  
     
     
         2 . Raw extract in accordance with  claim 1  characterised by the fact that the fungus is the Guignardia sp.  
     
     
         3 . Aqueous raw extract in accordance with  claim 2  characterised by the fact that the same is lyophilised.  
     
     
         4 . Organic raw extract in accordance with  claim 2  characterised by the fact that the extraction occurs with an organic solvent selected from the group consisting of hexane, cyclohexane, ethyl acetate, dichloromethane, methanol or ethanol.  
     
     
         5 . Organic raw extract in accordance with  claim 4  characterised by the fact that the extraction occurs with ethyl acetate.  
     
     
         6 . Organic raw extract in accordance with  claim 1  characterised by the fact of presenting activity against infections caused by fungi and bacteria.  
     
     
         7 . Pharmaceutical composition characterised by possessing as active ingredient an efficient quantity of the raw extract in accordance with  claim 1  and a pharmaceutically acceptable vehicle.  
     
     
         8 . Pharmaceutical composition in accordance with  claim 7  characterised by being used in the treatment of microbial infections, preferentially in the treatment of illnesses caused by filamentous fungi, yeasts, actynomycetes and bacteria.  
     
     
         9 . Pharmaceutical composition in accordance with  claim 8  characterised by the fact of being used in the treatment of infections caused by Gram negative bacteria.  
     
     
         10 . Pharmaceutical composition in accordance with  claim 9  characterised by the fact that the bacteria is the  Escherichia coli.    
     
     
         11 . Pharmaceutical composition in accordance with  claim 8  characterised by the fact of being used in the treatment of infections caused by Gram positive bacteria.  
     
     
         12 . Pharmaceutical composition in accordance with  claim 11  characterised by the fact that the bacteria is the  Staphylococcus aureus.    
     
     
         13 . Pharmaceutical composition in accordance with  claim 8  characterised by the fact of being used in the treatment of infections caused by filamentous fungi.  
     
     
         14 . Pharmaceutical composition in accordance with  claim 13  characterised by the fact that the fungi are the Geotrichum sp. or the  Penicillium canadensis.    
     
     
         15 . Pharmaceutical composition in accordance with  claim 8  characterised by the fact of being used in the treatment of infections caused by actinomycetes.  
     
     
         16 . Pharmaceutical composition in accordance with  claim 15  characterised by the fact that the actinomycete is the Actyno sp.  
     
     
         17 . Pharmaceutical composition in accordance with  claim 8  characterised by the fact that the active ingredient is present in a quantity varying between 1 and 50% in weight.  
     
     
         18 . Compound characterised by possessing the formula:  
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt of the same.  
     
     
         19 . Pharmaceutical composition characterised by including as active ingredient an efficient quantity of the compound in accordance with  claim 18  and a pharmaceutically acceptable vehicle.  
     
     
         20 . Pharmaceutical composition in accordance with  claim 19  characterised by being used in the treatment of microbial infections, preferentially in the treatment of illnesses caused by fungi and bacteria.  
     
     
         21 . Pharmaceutical composition in accordance with  claim 20  characterised by the fact of being used in the treatment of infections caused by Gram negative bacteria.  
     
     
         22 . Pharmaceutical composition in accordance with  claim 21  characterised by the fact that the bacteria is the  Escherichia coli.    
     
     
         23 . Pharmaceutical composition in accordance with  claim 20  characterised by the fact of being used in the treatment of infections caused by Gram positive bacteria.  
     
     
         24 . Pharmaceutical composition in accordance with  claim 23  characterised by the fact that the bacteria is the  Staphylococcus aureus.    
     
     
         25 . Pharmaceutical composition in accordance with  claim 21  characterised by the fact that the active ingredient is present in a quantity varying between 1 and 50% in weight.